Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The Single-Tablet Regimen (STaR) study (GS-US-264-0110) is a 96-week phase 3b study evaluating the safety and efficacy of 2 single-tablet regimens, rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF), and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) in treatment-naive HIV-1-infected subjects.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Acquir. Immune Defic. Syndr.

Title: Journal of acquired immune deficiency syndromes (1999)

ISSN (Electronic): 1944-7884

ISSN (Print): 1525-4135

Publication date (Electronic): Mar 1 2014

Volume: 65

Issue: 3

Affiliations

[1 ] Gilead Sciences, Inc, Foster City, CA.

Article

Publisher Item ID: 00126334-201403010-00011

DOI: 10.1097/QAI.0000000000000017

PubMed ID: 24525469

SO-VID: b55fb29f-a12e-4b64-a6e7-929bb30c6327

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 11

See all cited by